Journal article
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial
Abstract
BackgroundPositron emission tomography targeting the prostate specific membrane antigen (PSMA PET/CT) has demonstrated unparalleled performance as a staging examination for prostate cancer resulting in substantial changes in management. However, the impact of altered management on patient outcomes is largely unknown. This study aims to assess the impact of intensified radiotherapy or surgery guided by PSMA PET/CT in patients at risk of advanced …
Authors
Ménard C; Young S; Zukotynski K; Hamilton RJ; Bénard F; Yip S; McCabe C; Saad F; Brundage M; Nitulescu R
Journal
BMC Cancer, Vol. 22, No. 1,
Publisher
Springer Nature
Publication Date
12 2022
DOI
10.1186/s12885-022-09283-z
ISSN
1471-2407
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAntigens, NeoplasmCanadaClinical Trials, Phase III as TopicEquivalence Trials as TopicFluorine RadioisotopesGPI-Linked ProteinsHumansIntention to Treat AnalysisMaleNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasm StagingPositron Emission Tomography Computed TomographyPragmatic Clinical Trials as TopicProspective StudiesProstatectomyProstatic NeoplasmsRadiopharmaceuticalsRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedRandomized Controlled Trials as TopicSurgery, Computer-AssistedTreatment Outcome